ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
11 4월 2023 - 9:30PM
ReShape Lifesciences™ (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health solutions company, today announced that the company has
received a Notice of Allowance from the U.S. Patent and Trademark
Office (USPTO) for patent application 16/792,094, entitled,
“Systems and Methods for Determining Failure of Intragastric
Devices,” related to its Obalon® Balloon System. The patent will
cover additional claims for the Obalon® Balloon System and is
expected to provide protection into at least January 2031, without
accounting for a potential Patent Term Extension (PTE).
“Allowance of this patent significantly
strengthens our intellectual property portfolio around innovations
for the Obalon Intragastric Balloon System,” stated Paul F. Hickey,
President and Chief Executive Officer of ReShape Lifesciences.
“Since filing our first patent application in 2011, ReShape has
pioneered the field, amassing a patent family around the
intragastric balloon system, supported by a variety of novel,
pending and protected inventions. Going forward, we will continue
to build a defensive ‘moat’ around our product portfolio and
commercialization efforts, while also taking offensive action to
defend our patent position, when necessary.”
About ReShape
Lifesciences™ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. The recently launched
ReShape Marketplace™ is an online collection of quality wellness
products curated for all consumers to help them achieve their
health goals. The investigational Diabetes Bloc-Stim
Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve
block and stimulation technology platform for the treatment of Type
2 diabetes and metabolic disorders. The Obalon® balloon technology
is a non-surgical, swallowable, gas-filled intra-gastric balloon
that is designed to provide long-lasting weight loss. For more
information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor
Statement This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as "expect," "plan,"
"anticipate," "could," "may," "intend," "will," "continue,"
"future," other words of similar meaning and the use of future
dates. Forward-looking statements in this press release include
statements about our future intellectual property protection
measures. These and additional risks and uncertainties are
described more fully in the company's filings with the Securities
and Exchange Commission, including those factors identified as
"risk factors" in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q. We are providing this
information as of the date of this press release and do not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise, except as required by law.
CONTACTSReShape Lifesciences Investor
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
ReShape Lifesciences (NASDAQ:RSLS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024